Transparency notification of KBC Groep NV, KBC Bank NV, Compar Invest SA, Compar Finance SA, Banque Degroof SA, Degroof Corporate Finance SA, Imofig SA, Levimmo SA and Financière de Tubize SA, UCB SCA and UCB SA/NV

Participation on 23 August, 2011 (according to Article 14 of the law of May 2, 2007 on the disclosure of large shareholdings).

Brussels (Belgium), September 9, 2011 – 18.00 PM CET - regulated information – KBC Groep NV and KBC Bank NV, having their registered offices at Havenlaan 2, 1080 Brussels, Compar Invest SA, having its registered office Boulevard Grand Duchesse Charlotte 67, 1331 Luxemburg, Compar Finance SA, having its registered office rue Royale 97, 1000 Brussels, Banque Degroof SA, having its registered office rue de l’Industrie 44, 1040 Brussels, Degroof Corporate Finance SA, Imofig SA, Levimmo SA, having their registered offices rue Guimard 18, 1040 Brussels, Financière de Tubize SA and UCB SA/NV, both having their registered offices at Allée de la Recherche 60, 1070 Brussels, and UCB SCA having its registered office rue Eugène Ruppert 12, 2453 Luxemburg, notified that:

1. As a result of a sale of shares of UCB SA from KBC Groep NV and KBC Bank NV to UCB SA, Financière de Tubize SA, UCB SA, UCB SCA, UCB Fipar SA, KBC Groep NV and KBC Bank NV crossed a threshold for notification and are currently holding 74.217.759 shares (on a total number of 183.365.052) or 40.48% of UCB’s share capital or taking into account the 800.000 options previously purchased by UCB SA, 75.017.759 voting rights or 40.91% of the voting rights.

2. As a result of a sale of shares of UCB SA from Schwarz Vermögensverwaltung GmbH & Co KG to UCB SA, Financière de Tubize SA, UCB SA, UCB SCA, UCB Fipar SA, Compar Invest SA and Compar Finance SA crossed a threshold for notification and are currently holding 75.003.500 shares (on a total number of 183.365.052) or 40.90% of UCB’s share capital or taking into account the 800.000 options previously purchased by UCB SA, 75.803.500 voting rights or 41.34% of the voting rights.

3. As a result of a sale of shares of UCB SA from Schwarz Vermögensverwaltung GmbH & Co KG to UCB SA, Financière de Tubize SA, UCB SA, UCB SCA, UCB Fipar SA, Banque Degroof SA, Degroof Corporate Finance SA, Imofig SA and Levimmo SA crossed a threshold for notification and are currently holding 75.003.500 shares (on a total number of 183.365.052) or 40.90% of UCB’s share capital (or taking into account the 800.000 options previously purchased by UCB SA, 75.803.500 voting rights or 41.34% of the voting rights.

Please also refer to http://www.ucb.com/investors/shares/shareholder-structure/shareholders.

UCB S.A. - Allée de la Recherche, 60 - 1070 Brussels - RPM 0403.053.608

For further information
Antje Witte, Investor Relations, UCB
T +32.2.559.9414, antje.witte@ucb.com

Michael Tuck-Sherman, Investor Relations, UCB
T +32.2.559.9712, Michael.tuck-sherman@ucb.com

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 500 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB).

UCB Forward-looking statements
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.

Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.